Figure 1

CMA activity is elevated in human breast cancer. (A) Immunostaining for LAMP2A in normal breast epithelium tissues, fibroadenoma, breast cancer and metastatic lymph node tumor tissues (100× and 200×). (B) Immunoreactivity scores of LAMP2A levels in normal tissues, malignant carcinoma and metastatic carcinoma. (C) Immunoreactivity scores of LAMP2A in tumors of different histologic grades. Among all the invasive ductal carcinoma tumors, 21 were Grade I, 74 were Grade II, and 28 were Grade III. (D) Kaplan–Meier plots of LAMP2A expression in 19 cases of breast cancer patients. Overall survival rate was determined by the log-rank test. Each sample was assigned an immunoreactivity score that calculated the sum of the intensity of positive tumor cells (0 = none; 1 = weak; 2 = intermediate, 3 = strong) and the estimated fraction of positive staining tumor cells (0 = none, 1 ≤ 10%, 2 = 10–50% and 3 ≥ 50%) ranging from 0 and 2–6. We identified TMA scoring >3 as LAMP2A-positive tumors and TMA scoring ≤3 as LAMP2A-negative tumors (*P < 0.05, **P < 0.01).